Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

These can affect organs like kidneys, leading to conditions such as Lupus Nephritis and Rheumatoid ... Vitiligo, Psoriasis, Myositis, Multiple Sclerosis, Vasculitis, etc. Salient characteristics ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Cellares’ Cell Shuttle performed all unit operations in an automated manner, including cell isolation, enrichment, gene ...

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), has concluded the Technology Adoption ...

Envestnet Portfolio Solutions Inc. increased its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 7.9% in the 4th quarter, Holdings Channel reports. The firm owned 1,509 shares of the ...

(NASDAQ:ARGX – Get Free Report) was upgraded by investment analysts at Sanford C. Bernstein from a “market perform” rating to ...

The Technology Adoption Program successfully tested the ability of the Bridgewater Smart Factory to automate, lower costs and ...